Merck is a lonely hunter in CETP field
This article was originally published in Scrip
Executive Summary
One of the biggest elephants in Merck's clinic is anacetrapib. In Phase III studies that are not projected to read out until 2016/17, it sits hoovering up R&D dollars in a once-hyped cardiovascular space – CETP inhibition – that has fallen out of favor following high-profile late-stage failures at rival pharma powerhouses.